XNCR as reported
Xencor, Inc. reported $97M of revenue over the trailing twelve months, −23% on the year before. 10 reported series are charted on this page, each one as filed.
$97M
Revenue, trailing twelve months · to Q1 2026 · −23% against the twelve months before
- Net Income
- −$172M
Net Income · −17% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$189M
Free Cash Flow · +12% year on year · trailing twelve months to Q1 2026
- Op Margin
- −554%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $97M | −23% | Q1 2026 |
| Net Income | −$172M | −17% | Q1 2026 |
| EPS | −$2.29 | −25% | Q1 2026 |
| Op Margin | −554% | n/a | Q1 2026 |
| Net Margin | −744% | n/a | Q1 2026 |
| ROE | −24% | n/a | Q1 2026 |
| ROA | −17% | n/a | Q1 2026 |
| ROIC | −20% | n/a | Q1 2026 |
| Free Cash Flow | −$189M | +12% | Q1 2026 |
| P/E | 44.8 | n/a | Q3 2022 · 14 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Xencor, Inc. (XNCR) - Revenue & ProfitRevenue & ProfitXencor, Inc. (XNCR)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Biotechnology
The closest names by size in the same industry